All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”
EN
ČeštinaEnglish

Gefitinib in front line treatment of patients with NSCLC in the Czech republic: Analysis of 113 patients

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00077268" target="_blank" >RIV/00216224:14110/14:00077268 - isvavai.cz</a>

  • Result on the web

    —

  • DOI - Digital Object Identifier

    —

Alternative languages

  • Result language

    angličtina

  • Original language name

    Gefitinib in front line treatment of patients with NSCLC in the Czech republic: Analysis of 113 patients

  • Original language description

    Gefitinib is the active and selective EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor). This study evaluates treatment outcomes in 113 NSCLC patients with activating EGFR mutation.

  • Czech name

    —

  • Czech description

    —

Classification

  • Type

    O - Miscellaneous

  • CEP classification

    FC - Pneumology

  • OECD FORD branch

    —

Result continuities

  • Project

    —

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2014

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)

EGFR mutations in patients with advanced NSCLC.The importance of histology in patients with NSCLC and EGFR gene mutation.Rare and Common EGFR Mutations in Patients with Advanced NSCLC Treated with EGFR-TKIs: A Registry-Based Study